S. 3267 · 119th Congress · Health
ASAP Act
- IntroducedNov 20, 2025 Done
- CommitteeReferred to Finance Current stage
- Senate floorNot yet Not reached yet
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill provides for Medicare coverage of blood tests to screen for the early stages of Alzheimer’s disease or related dementias. Specifically, the bill provides for coverage of genomic sequencing blood or blood product tests, or other equivalent tests, that are approved by the Food and Drug Administration.
Congressional Research Service · summary of “Introduced in Senate” version · Nov 20, 2025
Who lobbies on it
5 organizations, more than 92% of Senate bills · 14 filings · Q4 2025–Q3 2026These 5 organizations’ PACs gave $137K to 23 of the 60 members sponsoring or cosponsoring S. 3267 in the 2025–26 election cycle.
One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Alzheimer's Association
4 of 4 quarters
“General issues related to detection, diagnosis and treatment of Alzheimer's and all other dementia; including the Alzheimer's Screening and Prevention Act of 2025 (H.R. 6130/S. 3267)”
$3.7M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Biogen
3 of 4 quarters
“…S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review…”
$3.4M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Eisai Inc.
2 of 4 quarters
“General issues related to Medicare and Medicaid, including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; enter for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers…”
$1.7M lobbying spend in 2026 to date, all issuesQ3 2026 filing
2 more organizations, every filingPROUpgrade
Organizations that named S. 3267 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- Nov 20, 2025Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S8278-8279)
- Nov 20, 2025Introduced in Senate
What members said about it
-
Advocates Passage of Alzheimer’s Screening and Prevention (ASAP) Act to Support Early Detection of Alzheimer’s and Dementia WASHINGTON — Today, Congressman Vern Buchanan, Vice Chairman of the House Ways and Means Committee and Chairman of…
“As someone who cared for a parent with this horrible disease, I believe that it is critical for Congress to recognize the impact that Alzheimer’s and dementia have on the millions of Americans diagnosed every year, as well as the caregivers who support them.”
-
Leading Alzheimer’s Advocates Urge Support for Buchanan’s ASAP Act
459 Organizations and Researchers Call on Congress to Fight Alzheimer’s: “The Need for Action is Urgent.”
“Early detection of Alzheimer’s disease is key to giving families more time, options and hope.”